

Fluidx Medical Announces First Patient Treated with Novel Embolic Gel

Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient.

SALT LAKE CITY, UT, UNITED STATES, April 2, 2026 /EINPresswire.com/ -- [Fluidx](#) Medical Technology, Inc. announced today that the first patient has been treated with the [ULTRA](#) Embolic Device. The ULTRA Embolic Device is intended for embolization of hypervascular tumors and blood vessels to occlude blood flow for controlling bleeding in the peripheral vasculature.

Globally, over 5 million embolization devices are used per year, but many of these devices are difficult to visualize, deliver, and control during the procedure. Other embolics have poor visibility, require complex preparation, and rely on difficult delivery techniques. The ULTRA Embolic Device was successfully used to treat an angiomyolipoma (AML) tumor. AMLs are the most common, solid renal tumor affecting between 0.3% and 0.6% of the global population.

“

We could see the material very well as it filled the vessel segment, completely blocking blood flow to the target area.”

Dr. Andrew Holden

“We are pleased with how controlled the material delivery was,” said Andrew Holden, M.D., Principal Investigator at Auckland City Hospital, in Auckland, New Zealand. “A testament to the technology, we felt comfortable delivering it in a difficult anatomical setting. We could see the material very well as it filled the vessel segment, completely blocking blood flow to the target area.”



The ULTRA Embolic Device is designed for use in embolization of tumors and peripheral vascular hemorrhage.

“The ULTRA Embolic Device was designed to provide maximum control to the physician,” said

Russ Bjorklund, Vice President, Fluidx Medical Technology, Inc. "Embolics should have consistent performance to maximize patient safety, be fast to prepare to reduce case times, and deliver complete results."

About Fluidx Medical Technology:

Fluidx Medical Technology, Inc. is a Salt Lake City, Utah based company focused on developing a new, innovative category of easy to use, controllable embolic gels that can treat the widest range of clinical conditions, effectively occluding the smallest vessels up to the largest vessels. The current pipeline includes the GPX, ULTRA, and IMPASS embolic technologies with applications across peripheral vascular, interventional oncology, and neurovascular embolization. Unlike other embolic devices, the Fluidx Medical Technology portfolio does not use toxic dimethyl sulfoxide (DSMO) or other precursors, glue catheters into the body, require special delivery systems, or need special mixers and preparation stations.

GPX, ULTRA, and IMPASS Embolic Devices are under development, described and shown for research, educational, and engineering use only, and do not have marketing clearance or approval in any market at this time.

www.FluidxMedical.com

Russell Bjorklund
Fluidx Medical Technology
[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/903159890>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.